Rerouting Minds is designed to increase understanding of pharmaceutical lysergide (LSD) and the role of rigorous psychedelic research in addressing unmet needs in severe mental health disorders

NEW YORK--(BUSINESS WIRE)--Jan. 20, 2026-- Definium Therapeutics, Inc.(formerly Mind Medicine (MindMed) Inc.), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the launch of Rerouting Minds, an educational campaign aimed at opening perspectives by increasing understanding and providing scientific context around pharmaceutical lysergide (LSD), exploring how it may support positive mental pathways and lasting progress in mental health care.

Nearly 1 in 4 adults, or roughly 59.3 million people in the U.S., live with a mental health disorder, and over 28 million do not receive treatment.^1,2 A growing body of promising evidence from well-controlled, scientifically rigorous clinical studies has emerged, exploring the potential of psychedelics, like LSD, to shape how we treat mental health disorders.³

“The disconnect between the human impact of psychiatric disorders and the lack of robustly effective and durable options in our treatment toolbox underscores the urgent need for new scientific approaches. That’s why methodologically sound clinical studies that investigate the clinical potential of psychedelics, like LSD, for the treatment of psychological distress, are so important and promising,” said Dan Karlin, Chief Medical Officer, Definium Therapeutics. “Our scientifically rigorous efforts within the psychedelic renaissance are reshaping how we understand LSD’s role in mental health care and as a potential next step in the treatment journey. The Rerouting Minds campaign highlights the science for clinicians and decision-makers, helping build awareness of the transformative potential of pharmaceutical LSD and what it can offer patients who are struggling in today’s mental health crisis.”

Rerouting Minds invites healthcare providers, psychiatrists, therapists, advocates, and policymakers to visit www.definiumtx.com/rerouting-minds to learn more about pharmaceutical lysergide (LSD) and its potential to improve mental health outcomes in certain mental health disorders. By exploring the Rerouting Minds campaign, individuals can learn about the medical history of LSD dating back to 1938, current scientific perspectives on how it may work in the brain, and access links to additional community resources.

Under the banner of the Rerouting Minds campaign, Definium Therapeutics continues its efforts to forge a new era of psychiatry by applying scientific rigor to psychedelics and fostering informed conversation and collaboration across the mental health landscape.

Explore the campaign at www.definiumtx.com/rerouting-minds/.

About Lysergide (LSD)

Lysergide (LSD) is one of the most extensively studied psychopharmaceuticals in history, with over 1,000 published reports.⁴ First synthesized in the 1930s by Swiss chemist Albert Hofmann in his search for active principles from ergot fungus, its profound psychological effects were discovered accidentally—an event that transformed psychiatric research.⁴ As a classic psychedelic, LSD temporarily alters perception, cognition, and emotions, while remaining physiologically safe, non-addictive, and free from withdrawal symptoms.⁴ While its precise mechanism of action in the treatment of psychiatric illness is unknown, mechanistic hypotheses suggest its acute perceptual, cognitive, and affective effects are mediated by agonism of the serotonin 5-hydroxytryptamine 2A (5-HT2A) receptor and sustained increases in neuroplasticity in a variety of brain regions.^5,6

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.

References:

1. Mental Illness. National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/mental-illness. Accessed November 2025.
2. Quick mental health facts and statistics. Mental Health America. https://mhanational.org/quick-facts/. Accessed December 2025.
3. Kurtz JS, et al. The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. Cureus. 2022;14(9):e29167.
4. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478
5. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics, 14, 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x
6. Liechti, M. E. (2017). Modern clinical research on LSD. Neuropsychopharmacology, 42, 2114–2127. https://doi.org/10.1038/npp.2017.86

View source version on businesswire.com: https://www.businesswire.com/news/home/20260115151547/en/

Investors:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media:
media@definiumtx.com

Source: Definium Therapeutics, Inc.